Lakeway, NY -- (SBWIRE) -- 03/22/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Gevo, Inc. (NASDAQ:GEVO) went up 2.72% and closed at $2.27. The Company partly prevailed in its bid for a federal court ruling that it doesn’t infringe a Butamax Advanced Biofuels LLC patent for a method to commercially produce isobutanol. U.S. District Judge Sue Robinson in Wilmington, Delaware ruled that “as a matter of law,” Gevo doesn’t infringe Butamax’s patent under the so-called doctrine of equivalents. The judge agreed with Gevo that the difference between its method and Butamax’s wasn’t insubstantial as Butamax argued.
Is GEVO a Strong After The recent price Movement? Let’s Find out Here
KB Home (NYSE:KBH) increased 2.46% and closed at $22.10. The Company released first quarter results. Revenues increased 59% to $405.2 million. The net loss declined 73%, to $12.5 million. On a per share basis, the Company’s net loss result also improved significantly to $.16 from $.59 in the year-earlier quarter.
Is KBH a Strong Buying Opportunity After The Recent Slump? Find out Here
Heckmann Corporation (NYSE:HEK) moved up 2.44% and closed at $4.20.Recently, the Company announced that it will unite its individual business units under a single new brand. Heckmann Corporation together with Heckmann Water Resources, Power Fuels and Thermo Fluids will become "Nuverra Environmental Solutions."
Is HEK Signaling a Buy Signal After The recent Volatility? Let’s Find out Here
Sarepta Therapeutics Inc. (NASDAQ:SRPT) moved up 2.41% and closed at $33.56. The median Wall Street price target on the stock is $45.0 and the high target is set at $65.0 with majority of analysts have a strong buy rating on the company’s stock. The stock has the 50- Day Moving Average and 200-Day Moving Average prices of $29.43 and $25.59 respectively. Sarepta Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of ribonucleic acid based therapeutics for the treatment of rare and infectious diseases.
Is SRPT a Strong Buying Opportunity After The Recent Gain? Find out Here
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)